ALXN.US

id: 822

Alexion (ALXN) $125M Shareholder Settlement

D. Connecticut

Court

3:16-cv-2127

Case number

01/30/2014

Class period Start

05/26/2017

Class period End

12/15/2023

Claim deadline

Alexion (ALXN) agreed to settle a $125 million with shareholders to end claims that the $ALXN caused a double-digit plunge in stock price after its allegedly illegal sales strategy came to light.

Case Status

Disbursement

Alleged Offence

Misleading Statements,

Failure to Disclose,

Omissions

Suspected Party

Directors,

Management

Security Type

Stocks

Trade Direction

Long

Payout per Share

0.76

Filing date

11/17/2016

Plaintiffs

Boston Retirement System, David A. Slossberg, Jeffrey P. Nichols

Attorneys

Labaton Sucharow LLP, Motley Rice LLC, Sturman LLC, Risch Pisca LLC

Defendants

Leonard Bell, David L. Hallal, Vikas Sinha

Judge

Hon. Alvin W. Thompson

Administrator

KCC

Settlement agreement date

2023-09-13

Court hearing date

12/20/2023

Exclusion deadline

11/29/2023

Objection deadline

11/29/2023

Hearing deadline

11/29/2023

Trades matching type

FIFO

Disbursement date

12/16/2024

+$125,000,000

Cash Settlement Amount

Alexion Pharmaceuticals Inc

Alexion Pharmaceuticals, Inc. develops and commercializes various therapeutic products. The company offers ULTOMIRIS for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemo...

Ticker

ALXN.US

ISIN

US0153511094

CIK

899866

Sector

Healthcare

Industry

Biotechnology

Country

USA

Address

121 Seaport Boulevard, Boston, MA, United States, 02210